Hormone Replacement Therapy In Rheumatoid Arthritis Is Associated With Lower Serum Levels of Soluble IL-6 Receptor and Higher Insulin-Like Growth Factor 1

Helena Forsblad d'Elia Lars-Åke Mattsson, Claes Ohlsson, Elisabeth Nordborg, Hans Carlsten


Arthritis Res Ther. 2003;5(4) 

In This Article


In summary, we found in this controlled clinical trial that the increase of E2 levels in serum was highly correlated with improved BMD. We have tried to elucidate possible ways, in the network of proinflammatory cytokines and IGF-1, by which HRT exerts its effects on the skeleton in long-lasting active RA. We found that HRT reduces serum levels of sIL-6R, whereas IGF-1 levels were observed to be increased. Both of these results - the effects on the IL-6/ sIL-6R pathway and on IGF-1 in the endocrine system - may be involved in the mechanisms mediating the beneficial effects of HRT. There is a need for larger, controlled, long-term studies of combined treatment in RA - estrogen plus progestogen, and estrogen alone - to support our results and to investigate the effects of the various hormones.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: